Day One Biopharmaceuticals
2000 Sierra Point Parkway
Suite 501
Brisbane
CA
94005
United States
Tel: 1-650-484-0899
Website: https://dayonebio.com/
Email: info@dayonebio.com
About Day One Biopharmaceuticals
Day One Biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. We are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. Our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. We are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
68 articles about Day One Biopharmaceuticals
-
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
2/26/2024
Day One Biopharmaceuticals announced its fourth quarter and full year 2023 financial results and highlighted recent corporate achievements.
-
Day One Announces Two New Appointments to Board of Directors
1/17/2024
Day One Biopharmaceuticals today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors.
-
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference
12/19/2023
Day One Biopharmaceuticals today announced that Dr. Jeremy Bender, chief executive officer, will present during the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8 at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time.
-
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
11/17/2023
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the investigational agent tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma in Nature Medicine.
-
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference
11/14/2023
Day One Biopharmaceuticals today announced that management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Tuesday, November 28 at 11:30 a.m. EST.
-
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress
11/6/2023
Day One Biopharmaceuticals announced its third quarter 2023 financial results and highlighted recent corporate achievements.
-
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
9/11/2023
Day One Biopharmaceuticals today announced the recently completed submission of the rolling New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tovorafenib as a monotherapy in relapsed or progressive pediatric low-grade glioma (pLGG).
-
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience
8/16/2023
Day One Biopharmaceuticals today announced it has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience for its VRK1 program.
-
Day One Reports Second Quarter 2023 Financial Results and Corporate Progress
8/7/2023
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced its second quarter 2023 financial results and highlighted recent corporate achievements.
-
Day One Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
6/12/2023
Day One Biopharmaceuticals, Inc. announced the closing on June 12, 2023 of its previously announced underwritten public offering of 13,269,231 shares of its common stock, including the full exercise of the underwriters’ option to purchase 1,730,769 additional shares, at a public offering price of $13.00 per share.
-
Day One Announces Pricing of Public Offering of Common Stock - June 07, 2023
6/7/2023
Day One Biopharmaceuticals, Inc. announced the pricing of its underwritten public offering of 11,538,462 shares of its common stock at a public offering price of $13.00 per share.
-
Day One Announces Proposed Public Offering of Common Stock - June 06, 2023
6/6/2023
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that it has commenced an underwritten public offering of $150.0 million of shares of its common stock.
-
Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma
6/4/2023
Day One Biopharmaceuticals announced new data from the registrational Phase 2 FIREFLY-1 trial evaluating the investigational agent tovorafenib.
-
Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference
5/30/2023
Day One Biopharmaceuticals announced management will participate in a fireside chat at the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14 at 11:20 a.m. PT.
-
CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/26/2023
Day One Biopharmaceuticals announced the publication of three abstracts on the American Society of Clinical Oncology website.
-
Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
5/25/2023
Day One Biopharmaceuticals, a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced the publication of three abstracts on the American Society of Clinical Oncology website.
-
Day One Reports First Quarter 2023 Financial Results and Corporate Progress
5/1/2023
Day One Biopharmaceuticals (Nasdaq: DAWN) today announced its first quarter 2023 financial results and highlighted recent corporate achievements.
-
Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
4/26/2023
Day One Biopharmaceuticals (Nasdaq: DAWN) today announced the acceptance of three abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting to take place in Chicago, IL from June 2 – 6, 2023.
-
Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress
4/12/2023
Day One Biopharmaceuticals announced an upcoming poster presentation at the 19th European Association of Dermato-Oncology Congress being held from April 20-22, 2023 in Rome, Italy.
-
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
3/6/2023
Day One Biopharmaceuticals announced its fourth quarter and full year 2022 financial results and highlighted recent corporate achievements.